OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103690-103690
Open Access | Times Cited: 33
Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103690-103690
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis
Adolfo del Canto, Claudia Cárcamo, Lorena Garcia, et al.
Multiple Sclerosis Journal (2025)
Closed Access | Times Cited: 1
Adolfo del Canto, Claudia Cárcamo, Lorena Garcia, et al.
Multiple Sclerosis Journal (2025)
Closed Access | Times Cited: 1
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 4-5, pp. 585-594
Open Access | Times Cited: 33
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 4-5, pp. 585-594
Open Access | Times Cited: 33
Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate
Marcin Bazylewicz, Monika Zajkowska, Monika Gudowska-Sawczuk, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 153-153
Open Access
Marcin Bazylewicz, Monika Zajkowska, Monika Gudowska-Sawczuk, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 153-153
Open Access
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
Wang Chun Kwok, Sze Him Isaac Leung, Terence Chi Chun Tam, et al.
International Journal of COPD (2023) Vol. Volume 18, pp. 47-56
Open Access | Times Cited: 13
Wang Chun Kwok, Sze Him Isaac Leung, Terence Chi Chun Tam, et al.
International Journal of COPD (2023) Vol. Volume 18, pp. 47-56
Open Access | Times Cited: 13
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
Niklas Frahm, Firas Fneish, David Ellenberger, et al.
The Lancet Regional Health - Europe (2022) Vol. 22, pp. 100502-100502
Open Access | Times Cited: 20
Niklas Frahm, Firas Fneish, David Ellenberger, et al.
The Lancet Regional Health - Europe (2022) Vol. 22, pp. 100502-100502
Open Access | Times Cited: 20
Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study
Carol Hitchon, Christine Mesa, Çharles N. Bernstein, et al.
BMJ Open (2023) Vol. 13, Iss. 5, pp. e071397-e071397
Open Access | Times Cited: 9
Carol Hitchon, Christine Mesa, Çharles N. Bernstein, et al.
BMJ Open (2023) Vol. 13, Iss. 5, pp. e071397-e071397
Open Access | Times Cited: 9
Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis
Lingyao Kong, Xiaofei Wang, Hongxi Chen, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104167-104167
Open Access | Times Cited: 13
Lingyao Kong, Xiaofei Wang, Hongxi Chen, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104167-104167
Open Access | Times Cited: 13
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 12
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 12
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
Sarah Conway, Shrishti Saxena, Clare Baecher‐Allan, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 5
Sarah Conway, Shrishti Saxena, Clare Baecher‐Allan, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 5
COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review
Marcin Bazylewicz, Monika Gudowska-Sawczuk, Barbara Mroczko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9231-9231
Open Access | Times Cited: 5
Marcin Bazylewicz, Monika Gudowska-Sawczuk, Barbara Mroczko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9231-9231
Open Access | Times Cited: 5
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
Asia‐Sophia Wolf, Anthony Ravussin, Marton König, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 4
Asia‐Sophia Wolf, Anthony Ravussin, Marton König, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 4
Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis
Theodoros Marantos, Evdoxia Kyriazopoulou, Vasileios Lekakis, et al.
Journal of the Neurological Sciences (2023) Vol. 456, pp. 122852-122852
Closed Access | Times Cited: 4
Theodoros Marantos, Evdoxia Kyriazopoulou, Vasileios Lekakis, et al.
Journal of the Neurological Sciences (2023) Vol. 456, pp. 122852-122852
Closed Access | Times Cited: 4
Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant
Jiajun Wu, Yong Wei, Feng Shen, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 7
Jiajun Wu, Yong Wei, Feng Shen, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 7
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Dominika Šťastná, Frederik Elberling, Luigi Pontieri, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 3
Open Access | Times Cited: 3
Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis
Fan Ning, Xiang-qi Cao, Qingqing Wang, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23944-e23944
Open Access | Times Cited: 3
Fan Ning, Xiang-qi Cao, Qingqing Wang, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23944-e23944
Open Access | Times Cited: 3
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 2
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 2
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 24-31
Open Access | Times Cited: 2
Massimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 24-31
Open Access | Times Cited: 2
Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders
Mohammad Yazdan Panah, Saeed Vaheb, Yousef Mokary, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126061-126061
Closed Access
Mohammad Yazdan Panah, Saeed Vaheb, Yousef Mokary, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126061-126061
Closed Access
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study
Berenice Anabel Silva, Esteban A. Miglietta, Juan Cruz Casabona, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Berenice Anabel Silva, Esteban A. Miglietta, Juan Cruz Casabona, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet’s syndrome
Ayşe Özdede, Okan Kadir Nohut, Zeynep Atlı, et al.
Rheumatology International (2022) Vol. 42, Iss. 10, pp. 1741-1750
Open Access | Times Cited: 3
Ayşe Özdede, Okan Kadir Nohut, Zeynep Atlı, et al.
Rheumatology International (2022) Vol. 42, Iss. 10, pp. 1741-1750
Open Access | Times Cited: 3
Central Nervous System Neuroimmunologic Complications of COVID-19
Kathryn B. Holroyd, Sarah Conway
Seminars in Neurology (2023) Vol. 43, Iss. 02, pp. 229-250
Closed Access | Times Cited: 1
Kathryn B. Holroyd, Sarah Conway
Seminars in Neurology (2023) Vol. 43, Iss. 02, pp. 229-250
Closed Access | Times Cited: 1
Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases
Daidi Zhao, Wenting Zhang, Xue Ma, et al.
Vaccine X (2023) Vol. 15, pp. 100388-100388
Open Access | Times Cited: 1
Daidi Zhao, Wenting Zhang, Xue Ma, et al.
Vaccine X (2023) Vol. 15, pp. 100388-100388
Open Access | Times Cited: 1
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study
Firas Fneish, Niklas Frahm, Melanie Peters, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1859-1859
Open Access | Times Cited: 1
Firas Fneish, Niklas Frahm, Melanie Peters, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1859-1859
Open Access | Times Cited: 1
